Cronidipine

TargetMol
Product Code: TAR-T27087
Supplier: TargetMol
CodeSizePrice
TAR-T27087-1mg1mg£188.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27087-5mg5mg£352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27087-10mg10mg£496.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27087-25mg25mg£760.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27087-50mg50mg£1,018.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27087-100mg100mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27087-500mg500mg£2,633.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Cronidipine, a calcium channel antagonist, is used potentially for the treatment of hypertension and myocardia ischemia.
CAS:
113759-50-5
Formula:
C30H32ClN3O8
Molecular Weight:
598.05
Pathway:
Membrane transporter/Ion channel|Metabolism
Purity:
0.98
SMILES:
COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCC1COC2(CCN(CC2)c2ccc(Cl)cc2)O1
Target:
Calcium Channel

References

Baillet G, et al. Radio high-performance liquid chromatographic determination of 14C-labelled LF 2-0254, A 1,4-dihydropyridine calcium antagonist, in rat and dog plasma using off-line liquid scintillation counting. J Chromatogr. 1988;456(1):183-190. Pruneau D, et al. Cardiovascular properties of LF 2.0254, a new potent vasoselective calcium channel blocker with a slow onset of action. Fundam Clin Pharmacol. 1990;4(2):223-243. Pruneau D, et al. Antihypertensive activity of a new calcium channel blocker LF 2.0254, in spontaneously hypertensive rats: a comparison with nifedipine and nicardipine. Arch Int Pharmacodyn Ther. 1988;295:109-124.